Integrated personalized cell technologies for improving health outcomes in children and adults

Report: Promising cell type represents new frontier for treating disease

A type of cell drawn from certain body tissues shows enormous potential to treat a range of diseases in the United States and Europe, but it must first receive federal approval as a regulated pharmaceutical.

That is the message of a recent report by a UW-Madison researcher. Jacques Galipeau, MD, director of the Program for Advanced Cell Therapy at the UW School of Medicine and Public Health, says mesenchymal stromal cells are the most-studied cell therapy that is not yet FDA-approved.

Read the full article at: